NasdaqGS:SBBP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. More Details


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has Strongbridge Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SBBP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: SBBP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

2.6%

SBBP

0.06%

US Pharmaceuticals

2.8%

US Market


1 Year Return

52.5%

SBBP

5.6%

US Pharmaceuticals

20.9%

US Market

Return vs Industry: SBBP exceeded the US Pharmaceuticals industry which returned 5.6% over the past year.

Return vs Market: SBBP exceeded the US Market which returned 20.9% over the past year.


Shareholder returns

SBBPIndustryMarket
7 Day2.6%0.06%2.8%
30 Day41.5%6.4%11.1%
90 Day-28.1%-2.0%6.5%
1 Year52.5%52.5%8.4%5.6%23.6%20.9%
3 Year-59.1%-59.1%23.8%14.7%47.3%37.6%
5 Year-53.1%-53.1%36.2%20.6%94.3%72.9%

Long-Term Price Volatility Vs. Market

How volatile is Strongbridge Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Strongbridge Biopharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SBBP ($2.76) is trading below our estimate of fair value ($46.37)

Significantly Below Fair Value: SBBP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SBBP is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: SBBP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SBBP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SBBP is good value based on its PB Ratio (2.5x) compared to the US Pharmaceuticals industry average (3.6x).


Next Steps

Future Growth

How is Strongbridge Biopharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

58.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SBBP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SBBP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SBBP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SBBP's revenue (46.2% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: SBBP's revenue (46.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SBBP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Strongbridge Biopharma performed over the past 5 years?

17.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SBBP is currently unprofitable.

Growing Profit Margin: SBBP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SBBP is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.

Accelerating Growth: Unable to compare SBBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SBBP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: SBBP has a negative Return on Equity (-56.47%), as it is currently unprofitable.


Next Steps

Financial Health

How is Strongbridge Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: SBBP's short term assets ($87.4M) exceed its short term liabilities ($19.4M).

Long Term Liabilities: SBBP's short term assets ($87.4M) exceed its long term liabilities ($23.7M).


Debt to Equity History and Analysis

Debt Level: SBBP's debt to equity ratio (9.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if SBBP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SBBP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SBBP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Strongbridge Biopharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SBBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SBBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SBBP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SBBP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SBBP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

John Johnson (62 yo)

0.33

Tenure

US$1,163,199

Compensation

Mr. John H. Johnson serves as Chief Executive Officer at Strongbridge Biopharma plc since July 7, 2020. Mr. Johnson serves as Director at Verastem, Inc. since April 2020. He served as Acting Chief Executiv...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.16M) is about average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Johnson
Chief Executive Officer0.33yrUS$1.16m0.037%
$ 68.0k
Robert Lutz
Chief Financial Officer1.17yrsUS$1.02m0.019%
$ 35.5k
Richard Kollender
Chief Operating Officer1.17yrsUS$173.64k0.17%
$ 323.4k
Fredric Cohen
Chief Medical Officer4yrsUS$1.09m0.020%
$ 37.1k
Per Marin
Founder and Senior Clinical Advisorno datano datano data
Peter Valentinsson
Senior Vice President of Global Technical Operations3.67yrsno datano data
Stephen Long
Chief Legal Officer & Company Secretary5.67yrsno datano data
Brian Conner
Chief Compliance Officerno datano datano data
Dave Bonnell
Senior Vice President of Sales & Marketing3.83yrsno datano data
Emily Doyle
Chief Human Resources Officer1.67yrsno datano data
Scott Wilhoit
Chief Commercial Officer3.83yrsno data0.0091%
$ 17.0k

3.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: SBBP's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Johnson
Chief Executive Officer0.33yrUS$1.16m0.037%
$ 68.0k
David Gill
Independent Director1.17yrsUS$150.17k0.052%
$ 96.3k
Garheng Kong
Independent Chairman0.33yrUS$174.96k0.031%
$ 57.8k
Hilde Steineger
Independent Director6.83yrsUS$173.32k0.031%
$ 57.9k
Beverly M. Biller
Member of Scientific Advisory Boardno datano datano data
Mårten Steen
Independent Director5.92yrsUS$181.46k0.031%
$ 57.7k
Richard Auchus
Member of Scientific Advisory Boardno datano datano data
Thierry Brue
Member of Scientific Advisory Boardno datano datano data
Frederic Castinetti
Member of Scientific Advisory Boardno datano datano data
Maria Fleseriu
Member of Scientific Advisory Boardno datano datano data
Eliza Geer
Member of Scientific Advisory Boardno datano datano data
Anthony Heaney
Member of Scientific Advisory Boardno datano datano data

5.7yrs

Average Tenure

54yo

Average Age

Experienced Board: SBBP's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SBBP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.1%.


Top Shareholders

Company Information

Strongbridge Biopharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Strongbridge Biopharma plc
  • Ticker: SBBP
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$185.593m
  • Shares outstanding: 67.24m
  • Website: https://www.strongbridgebio.com

Number of Employees


Location

  • Strongbridge Biopharma plc
  • 900 Northbrook Drive
  • Suite 200
  • Trevose
  • Pennsylvania
  • 19053
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SBBPNasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDJan 2000
69BNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2000

Biography

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an or...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/29 23:29
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.